Table 3.
Antiproliferative activities (IC50) of the synthesized apigenin derivatives against A549, HeLa, HepG2, and MCF-7 cell lines.
| Compounds | IC50 (μg/mL) | |||
|---|---|---|---|---|
| A549 | HeLa | HepG2 | MCF-7 | |
| Apigenin (1) | 1,740 ± 3.4 | 450 ± 2.0 | 460 ± 2.2 | >2,000 ± 3.6 |
| 2a | 643 ± 4.2 | 590 ± 4.1 | 408 ± 3.8 | 534 ± 3.4 |
| 2b | 251 ± 3.4 | 233 ± 2.2 | 176 ± 2.1 | 209 ± 2.8 |
| 3a | 101 ± 3.0 | 110 ± 2.0 | 116 ± 2.3 | 125 ± 2.2 |
| 3b | 94 ± 2.5 | 109 ± 1.9 | 103 ± 1.9 | 102 ± 2.1 |
| 3c | 87 ± 2.2 | 98 ± 1.5 | 105 ± 1.4 | 114 ± 1.9 |
| 3d | 80 ± 1.5 | 117 ± 2.1 | 112 ± 2.0 | 137 ± 2.6 |
| 3e | 78 ± 1.6 | 97 ± 1.8 | 92 ± 1.8 | 99 ± 2.0 |
| 3f | 83 ± 2.3 | 89 ± 1.4 | 96 ± 1.5 | 92 ± 2.0 |
| 3g | 42 ± 2.1 | 32 ± 1.2 | 33 ± 1.2 | 71 ± 1.2 |
| 3h | 45 ± 1.7 | 46 ± 1.0 | 43 ± 1.7 | 70 ± 1.8 |
| 3i | 39 ± 0.9 | 42 ± 0.9 | 36 ± 1.0 | 54 ± 1.1 |
| 3j | 26 ± 1.0 | 17 ± 0.8 | 29 ± 1.2 | 49 ± 1.4 |
| 4a | 91 ± 2.4 | 99 ± 2.3 | 100 ± 2.8 | 99 ± 2.1 |
| 4b | 85 ± 2.1 | 83 ± 1.7 | 94 ± 2.2 | 87 ± 2.3 |
| 4c | 72 ± 1.8 | 81 ± 1.3 | 82 ± 1.8 | 95 ± 2.8 |
| 4d | 63 ± 1.1 | 101 ± 2.6 | 83 ± 1.7 | 103 ± 3.1 |
| 4e | 62 ± 1.5 | 86 ± 2.0 | 90 ± 2.0 | 88 ± 2.9 |
| 4f | 70 ± 2.2 | 75 ± 1.3 | 89 ± 1.4 | 89 ± 3.3 |
| 4g | 32 ± 1.4 | 27 ± 1.1 | 31 ± 1.0 | 59 ± 2.0 |
| 4h | 35 ± 2.0 | 34 ± 1.5 | 44 ± 1.2 | 50 ± 2.3 |
| 4i | 27 ± 1.3 | 19 ± 1.0 | 28 ± 1.1 | 47 ± 1.9 |
| 4j | 16 ± 1.0 | 11 ± 1.1 | 25 ± 1.6 | 32 ± 1.8 |